|
|
BUILD YOUR OWN PROGRAM
CHOOSE FROM 3 TRACKS
| TRACK
A |
BASIC
RESEARCH & DISCOVERY |
| TRACK
B |
PRECLINICAL
DEVELOPMENT |
| TRACK
C |
CLINICAL
OPERATIONS |
|
COMPLIMENTARY
PRE-CONFERENCE TUTORIAL: |
|
Planning a Global
Strategy Around Intellectual Property Law: IP Barriers and Trends |
|
INTERACTIVE
PANELS: |
|
Partner, Buy or Build
Your Own?
Strategies for Optimizing Preclinical Outsourcing in India and China
Value Chain of Outsourcing R&D Services in Russia
Effective Organizational Models and Strategies for Global Clinical
Trials |
|
ROUNDTABLE
DISCUSSIONS: |
|
Concurrent
interactive roundtables discussing some of the more
poignant questions facing the industry… |
|
|
FEATURED PRESENTATIONS AND PANELS:
| |
|
 |
Roche’s
Investment in R&D in China: Understanding the Political, Economic,
and Financial Challenges
Lee Babiss, Ph.D., Vice President, Preclinical Research and Development,
Roche |
| |
|
|
Clinical
Development in India and China: Opportunities for Integration in Global
Development
Mark Bach, Ph.D., Vice President, Clinical Research Operations Worldwide,
Merck & Co. |
| |
|
 |
Gregg C. Benson, Assistant General Counsel - Intellectual Property, Pfizer Inc. |
| |
|
 |
Gregory E. Kalbaugh, Director and Counsel for Intellectual Property, Trade and Labor, US-India Business Council, US Chamber of Commerce |
| |
|
|
Clinical
Development in Asia Pacific: Opportunities and Challenges
Lily W. Lee, Ph.D., Vice President, Head of Asia Pacific, Johnson and Johnson |
| |
|
|
Tapping
into Emerging Capabilities of Academic Centers in Asia
Michael N. Liebman, Ph.D., Executive Director, Windber Research
Institute |
| |
|
 |
Short and
Long Term Strategic Planning for Clinical Development Operations in
Emerging Regions
Robert Maguire, M.D., Vice President, Clinical Development and Chief of
Operations, Wyeth
Pharmaceuticals |
| |
|
 |
Kenneth A. Savin, Head of the Discovery Chemistry Global Operations Group, Discovery Chemistry, Eli Lilly and Co. |
| |
|
 |
Strategic
Planning for China and India Entry: Perspectives from a Large
Biotechnology Company
Whaijen Soo, M.D., Ph.D., Senior Vice President, Medical Research, Biogen
Idec |
| |
|
TRACK
A
BASIC RESEARCH & DISCOVERY |
TRACK
B
PRECLINICAL DEVELOPMENT |
TRACK
C
CLINICAL OPERATIONS |
-
Tapping
into Emerging Capabilities of Academic Centers
in Asia
-
Practical
Implications of Moving from Traditional
to Transformational Outsourcing Models
-
Value
Chain of Outsourcing R&D Services in Russia
-
Strategies
for Procurement for Discovery and Development
in a Free-Market Economy
-
Partnering
and Investing Strategies by Big Pharma
and Large Biotech Companies
-
Working
with European and Asian governments to
access novel funding mechanisms for collaborative research
|
-
Outsourcing
Preclinical Toxicology Studies or Partnering
to Build Western Quality GLP Tox Facilities:
New Requirements and Regulations for Both
Paths
-
Leveraging
Omics in India to Improve Your Drug Development
Strategy
-
Strategies
for Optimizing Preclinical Outsourcing:
Working with your Provider to Kill Unsuccessful
Compounds and Promote Promising Candidates
Faster
-
Understanding
the Opportunities, True Costs and
Limitations of In Vivo Preclinical Testing in Asia
|
-
Short
and Long Term Strategic Planning for Clinical
Development Operations in Emerging Regions
-
Effective
Organizational Models and Strategies to Leverage
Global Capabilities in Different Regions
-
Understanding
the Architecture and Processes of a
Successful Outsourced Global Clinical/Hospital Supply
Chain
-
Designing
and Implementing Clinical Trials that will
withstand Inspections from Global Regulatory
Authorities
-
Where
are the Trials Going and Why?
|
Distinguished Faculty:
-
Lee Babiss, Ph.D., Vice President, Preclinical Research and Development,
Roche
-
Mark A. Bach, Ph.D., Vice President, Clinical Research Operations Worldwide,
Merck & Co.
-
Balu Balasubramanian, Ph.D., Director, Discovery Chemistry, Bristol-Myers
Squibb Co.
-
Steve Bjornson, MBA, Associate Director, Discovery Research Strategy,
Wyeth Pharmaceuticals
-
Beth Bookland, Ph.D., Director, Clinical Operations,
Procter & Gamble Pharmaceuticals
-
Andrew C. Chang, Ph.D., Senior Director,
PharmaNet Consulting
-
Duke Danont, Senior Project Manager, Global Distribution,
Amgen
-
Parimal R. Desai, Vice President, Analytical and Quality Sciences,
Wyeth Pharmaceuticals
-
Rakesh Dixit, Ph.D., DABT, Senior Director and Head, Toxicology,
MedImmune, Inc.
-
Sara Friedlander, Ph.D., Director, Global Strategic Sourcing,
Bristol-Myers Squibb Co.
-
Kenneth A. Getz, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development and Chairman and Founder,
CISCRP
-
Simon Greenwood, Ph.D., Senior Manager, Business Development,
Genentech, Inc.
-
Martin Hauses, Outsourcing Manager,
Merck KGaA
-
Katsumi Ishiguro, Manager, Licensing & Business Development,
Kaken Pharmaceutical Co., Ltd.
-
Mak Jawadekar, Ph.D., Director,
WWPM, Pfizer Global R&D
-
Gregory E. Kalbaugh, Director and Counsel for Intellectual Property, Trade and Labor, US-India Business Council,
US Chamber of Commerce
-
Gopala Krishna, PhD, DABT, MBA, Senior Director and Head, Department of Preclinical Candidate Evaluation,
Supernus Pharmaceuticals, Inc.
-
Ada Kung, Ph.D.,DABT, MBA, Chief Technical Officer, Senior Vice President, Operations and Product Development,
Bridge Pharmaceuticals, Inc.
|
-
Sundeep Lal, Ph.D., MBA, Senior Director, New Products / Licensing, Global Human Health,
Merck & Co.
-
Lily W. Lee, Ph.D., Vice President, Head of Asia Pacific,
Johnson and Johnson
-
Chris Song, Manager, Pharmaceutical Segment, Applied
Biosystems, former Special Project Manager, AstraZeneca R&D,
China
-
Michael N. Liebman, Ph.D., Executive Director,
Windber Research Institute
-
Robert Maguire, M.D., Vice President, Clinical Development and Chief of Operations,
Wyeth
-
Joel S. Marcus, Chief Executive Officer,
Alexandria Real Estate Equities, Inc.
-
Laura Meyerson, Ph.D., Vice President and Head of Biometrics,
Biogen Idec
-
Suresh Poosala DVM, Ph.D., Chief of Comparative Medicine and Animal Program Director,
NIH
-
Ted Quiroz, Director, Clinical Supply Chain,
Amgen
-
Judith Reece, Ph.D., Director, R&D Strategic Planning, Development Affairs,
AstraZeneca
-
James Resch, Ph.D., Director, Strategic Planning, Global Discovery Affairs,
AstraZeneca
-
Nikolay Savchuk, Ph.D., President & Chief Executive Officer,
ChemDiv, Inc.
-
Kenneth Savin, Ph.D., Head of the Discovery Chemistry Global Operations Group, Discovery Chemistry,
Eli Lilly
-
Whaijen Soo, M.D., Ph.D., Senior Vice President, Medical Research,
Biogen Idec
-
Gangadhar Sunkara, Ph.D., MBA, Associate Director, Exploratory Development,
Novartis
-
Fabio A. Thiers, M.D., Research Fellow, MIT Center for Biomedical Innovation,
Harvard-MIT Division of Health Sciences & Technology
-
Ahsan A. Awan, JD, MBA, Chief Executive Officer,
Global CINRG, Inc.
-
Kamesh Venugopal, President,
Torrent Pharmaceuticals Ltd.
-
Gene Williams, Chief Executive Officer,
Cambridge Healthtech Associates
|
|
